Skip to main content Skip to main navigation menu Skip to site footer
logo Mediterranean Journal of Hematology and Infectious Diseases

eISSN 2035-3006

  • Home
  • About the Journal
  • Editorial Board
  • Current
  • Archives
  • Announcements
  • Register
  • Login
  • Journal Statistics
  • Search
  • Contact
  • Announcements

Editor-in-Chief: Giuseppe Leone | Italy

2.3
Impact Factor 2025
3.2
CiteScore 2025
2.3
Impact Factor 2025
3.2
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

    Monia Marchetti , Robert Peter Gale, Giovanni Barosi
    Page e2021034
    2021-04-29
    https://doi.org/10.4084/MJHID.2021.034
    1659
    PDF: 619
    HTML: 271
  • TREATMENT OF NEWLY DIAGNOSED POEMS SYNDROME: BORTEZOMIB OR LENALIDOMIDE? EXPERIENCE FROM TWO COUNTRIES

    Deniz Ozmen, Francesco Autore, Tuba Ozkan, Gunel Musayeva, Zeliha Birsin, Daniele Mannina, Federica Lessi, Daniele Derudas, Umut Yilmaz, Tugrul Elverdi, Ahmet Emre Eskazan, Muhlis Cem Ar, Zafer Baslar, Stefania Bramanti, Luca Laurenti, Ayse Salihoglu
    e2026084
    2026-10-31
    https://doi.org/10.4084/MJHID.2026.084
    115
    PDF: 59
    Suppl. Files: 19
    Html: 16
    Html Suppl. Files: 20
  • Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

    Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
    e2025026
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.026
    2171
    PDF: 1813
    HTML: 494
  • Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

    Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain
    e2010012
    2010-05-31
    https://doi.org/10.4084/mjhid.2010.012
    1139
    PDF: 744
    HTML: 385
  • Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

    Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
    e2025027
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.027
    1601
    PDF: 1365
    HTML: 796
  • Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large b-cell lymphoma.

    Emanuele Cencini, Alberto Fabbri, Umberto Arrigucci, Alfonso Cerase, Monica Bocchia
    e2017040
    2017-06-16
    https://doi.org/10.4084/mjhid.2017.040
    3649
    PDF: 1155
    HTML: 1056
    Figure 1: 287
  • LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

    Patrizia Tosi
    e2013037
    2013-06-03
    https://doi.org/10.4084/mjhid.2013.037
    1498
    PDF: 995
    HTML: 1312
    fig 1A: 251
    figure1B: 212
  • RECENT ADVANCES IN THE 5Q- SYNDROME

    Andrea Pellagatti, Jacqueline Boultwood
    e2015037
    2015-05-20
    https://doi.org/10.4084/mjhid.2015.037
    3198
    PDF: 1974
    HTML: 3853
    Pellagatti Fig 1: 282
    Pellagatti Fig. 2: 264
  • Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy

    Antonella Vaccarino, Irene Dogliotti, Fabio Marletto, Andrea Demarchi, Mario Bazzan
    e2016050
    2016-10-20
    https://doi.org/10.4084/mjhid.2016.050
    2992
    PDF: 838
    HTML: 1341
    Blood Count trend before and during lenalidomide treatment: 246
    Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 246
  • INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

    Giuseppe Leone, Livio Pagano
    e2018039
    2018-07-01
    https://doi.org/10.4084/mjhid.2018.039
    4519
    PDF: 1552
    HTML: 817
  • Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

    Daniele Derudas
    e2025025
    2025-02-27
    https://doi.org/10.4084/MJHID.2025.025
    1799
    PDF: 1489
    HTML: 198
  • ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

    Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko
    e2018014
    2018-02-15
    https://doi.org/10.4084/mjhid.2018.014
    5540
    PDF: 2070
    HTML: 2389
  • POEMS SYNDROME: AN UPDATE

    Andrea Nozza
    e2017051
    2017-09-01
    https://doi.org/10.4084/mjhid.2017.051
    3598
    PDF: 1777
    HTML: 1838
  • NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

    Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso
    e2010021
    2010-08-11
    https://doi.org/10.4084/mjhid.2010.021
    2170
    PDF: 2052
    HTML: 813
  • THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

    Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson
    e2010009
    2010-05-03
    https://doi.org/10.4084/mjhid.2010.009
    2213
    PDF: 804
    HTML: 686
  • The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

    Michele Bibas
    e2024015
    2024-02-29
    https://doi.org/10.4084/MJHID.2024.015
    2650
    PDF: 1865
    HTML: 1144
  • UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

    Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani
    e2012069
    2012-11-05
    https://doi.org/10.4084/mjhid.2012.069
    2721
    PDF: 814
    HTML: 1660
  • Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

    Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain
    e2010005
    2010-04-20
    https://doi.org/10.4084/mjhid.2010.005
    1270
    PDF: 634
    HTML: 1209
  • Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

    Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello
    e2025043
    2025-04-30
    https://doi.org/10.4084/MJHID.2025.043
    1312
    PDF: 1052
    HTML: 529
  • Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

    Jacopo Monticelli, Roberto Luzzati, Cristina Maurel, Chiara Rosin, Romina Valentinotti, Claudio Farina
    e2015011
    2014-12-24
    https://doi.org/10.4084/mjhid.2015.011
    1824
    PDF: 1161
    HTML: 6577
    original file with images: 343
  • Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

    Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia
    e2012041
    2012-06-19
    https://doi.org/10.4084/mjhid.2012.041
    1235
    PDF: 822
    HTML: 783
  • THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

    Xenofon Papanikolaou, Bart Barlogie, Saad Usmani
    e2011047
    2011-10-24
    https://doi.org/10.4084/mjhid.2011.047
    2674
    PDF: 886
    HTML: 1767
  • APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

    Tadeusz Robak
    e2010011
    2010-05-07
    https://doi.org/10.4084/mjhid.2010.011
    1775
    PDF: 717
    HTML: 2457
  • PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

    Giuseppe G.M. Leone, Ugo Testa
    e2025080
    2025-10-31
    https://doi.org/10.4084/MJHID.2025.080
    1808
    PDF: 462
    Html: 285
  • Ixazomib-associated skin exfoliation

    Yali Zhang, Long Zhao, Yuancheng Guo, bei liu
    e2022045
    2022-04-28
    https://doi.org/10.4084/MJHID.2022.045
    1015
    PDF: 646
    HTML: 268
  • NOVEL DRUGS IN FOLLICULAR LYMPHOMA

    Giuseppe Rossi, Antonella Anastasia
    e2016061
    2016-11-01
    https://doi.org/10.4084/mjhid.2016.061
    6016
    PDF: 1632
    HTML: 1689
    Untitled: 291
  • FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

    Alessia Castellino, Umberto Vitolo
    e2017009
    2017-01-01
    https://doi.org/10.4084/mjhid.2017.009
    4798
    PDF: 1766
    HTML: 4371
    Tables and Images: 310
  • "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

    Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro
    e2010013
    2010-06-01
    https://doi.org/10.4084/mjhid.2010.013
    1597
    PDF: 729
    HTML: 1603
  • THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

    May Basood, Howard S. Oster, Moshe Mittelman
    e2018046
    2018-07-01
    https://doi.org/10.4084/mjhid.2018.046
    3421
    PDF: 1494
    HTML: 754
  • LIGHT CHAIN AMYLOIDOSIS

    Paolo Milani, Giampaolo Merlini, Giovanni Palladini
    e2018022
    2018-03-01
    https://doi.org/10.4084/mjhid.2018.022
    6596
    PDF: 2517
    HTML: 1590
  • Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

    Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni
    e2025045
    2025-04-30
    https://doi.org/10.4084/MJHID.2025.045
    1906
    PDF: 1453
    HTML: 682
  • RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

    Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone
    e2023062
    2024-06-29
    https://doi.org/10.4084/MJHID.2024.062
    1465
    PDF: 1168
    HTML: 282
  • THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

    Francesco Maura, Lucia Farina, Paolo Corradini
    e2016045
    2016-09-01
    https://doi.org/10.4084/mjhid.2016.045
    4259
    PDF: 1258
    HTML: 2138
    Fig.1: 250
    Fig. 2: 149
    Table 1: 260
    Table2: 282
    Table 3: 270
  • SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

    Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca
    e2016062
    2016-11-06
    https://doi.org/10.4084/mjhid.2016.062
    4000
    PDF: 1169
    HTML: 2592
  • HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

    Mazyar Shadman, Joachim Deeg
    e2014056
    2014-09-01
    https://doi.org/10.4084/mjhid.2014.056
    2267
    PDF: 860
    HTML: 3292
  • REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

    Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst
    e2021012
    2021-01-01
    https://doi.org/10.4084/mjhid.2021.012
    1790
    PDF: 829
    HTML: 1524
  • SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

    Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil
    e2021006
    2021-01-01
    https://doi.org/10.4084/mjhid.2021.006
    2371
    PDF: 944
    HTML: 389
  • The possible role of chronic infection in the etiopathogenesis of a case of 5q-syndrome associated with tuberculosis and abnormality of the X chromosome.

    Lubomir Mitev
    e2022079
    2022-10-29
    https://doi.org/10.4084/MJHID.2022.079
    1634
    PDF: 606
    HTML: 326
  • PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY

    Alfredo Molteni, Emanuele Ravano, Marta Riva, Michele Nichelatti, Laura Bandiera, Lara Crucitti, Mauro Truini, Roberto Cairoli
    e2019015
    2019-02-26
    https://doi.org/10.4084/mjhid.2019.015
    2026
    PDF: 1060
    HTML: 367
  • ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA

    Luca Laurenti, Michela Tarnani, Patrizia Chiusolo, Federica Sorà, Simona Sica
    e2010026
    2010-08-31
    https://doi.org/10.4084/mjhid.2010.026
    1544
    PDF: 889
    HTML: 1045
  • EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

    Pellegrino Musto, Dr. Nicola Sgherza
    e2024073
    2024-08-31
    https://doi.org/10.4084/MJHID.2024.073
    1716
    PDF: 923
    HTML: 374
  • TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

    Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi
    e2023038
    2023-06-29
    https://doi.org/10.4084/MJHID.2023.038
    2523
    PDF: 1953
    HTML: 1095
  • FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

    Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni
    e2024066
    2024-08-31
    https://doi.org/10.4084/MJHID.2024.066
    1165
    PDF: 693
    Html: 188
  • RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

    Julie Schanz, Friederike Braulke, Detlef Haase
    e2015034
    2015-04-23
    https://doi.org/10.4084/mjhid.2015.034
    4030
    PDF: 1797
    HTML: 11990
    Figures Haase: 313
  • LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1

    kang sun
    e2024037
    2024-04-30
    https://doi.org/10.4084/MJHID.2024.037
    3119
    PDF: 1200
    HTML: 140
  • IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA

    Ugo Testa, Prof. Leone, Dr. Elvira Pelosi, Dr. Germana Castelli, Prof, Valerio De Stefano
    e2024044
    2024-04-30
    https://doi.org/10.4084/MJHID.2024.044
    2739
    PDF: 1274
    HTML: 180
  • CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA

    Michele Bibas, Jorge J Castillo
    e2014064
    2014-10-22
    https://doi.org/10.4084/mjhid.2014.064
    2774
    PDF: 1762
    HTML: 2471
    Table1: 303
  • EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

    Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan
    e2026033
    2026-04-30
    https://doi.org/10.4084/MJHID.2026.033
    470
    PDF: 421
    Suppl. Files: 110
    HTML: 136
  • THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

    Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso
    e2023064
    2023-10-30
    https://doi.org/10.4084/MJHID.2023.064
    1661
    PDF: 1043
    HTML: 275
  • THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

    Elihu Estey
    e2013050
    2013-07-12
    https://doi.org/10.4084/mjhid.2013.050
    2332
    PDF: 844
    HTML: 1654
1 - 50 of 91 items 1 2 > >> 
Make a Submission

Links

  • Editorial Board
  • Alert me!
  • Advertising
  • Scopus
  • DOAJ
  • Article Processing Charge

Information

  • For Readers
  • For Authors
  • For Librarians

Indexing

  • OpenAlex
  • Analytics

PubMed

MJHID CiteScore by Scopus

Clarivate Analytics

this journal is covered
by Clarivate Analytics

 

The Mediterranean Journal of Hematology and Infectious Diseases has been selected for coverage in Clarivate Analytics products and services. Beginning with V. 7 (1) 2015.

AskBisht

Indexed in AskBisht.com

Facebook

FOLLOW US

MJHID in EuroPub Database

EuroPub

CLL UpDate

Keywords

Mediterranean Journal of Hematology and Infectious Diseases

is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. The MJHID is indexed and abstracted in Science Citation Index Expanded and Journal Citation Reports/InCites beginning with V. 7 (1) 2015.

eISSN: 2035-3006

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.